9/11/2026
Ibogaine's potential in opioid addiction treatment
Ibogaine offers a novel approach to opioid detox, but carries significant risks.
Topic archive
40 stories
9/11/2026
Ibogaine offers a novel approach to opioid detox, but carries significant risks.
9/10/2026
Filament Health begins stability program for IBEX011 amid rising ibogaine demand.
9/10/2026
IBEX011 stability program aims to meet growing demand for standardized ibogaine.
8/26/2026
The move promotes open science and could influence future psychedelic research.
8/21/2026
The move could expedite psychedelic research for veteran treatment.
8/21/2026
David Dardashti shares clinical footage as psychedelic therapy gains federal interest.
8/19/2026
Market optimism grows as Psyence Biomedical advances ibogaine studies.
8/19/2026
Former President Trump supports ibogaine research, sparking industry response.
8/19/2026
Company aligns with U.S. efforts to advance ibogaine research.
8/19/2026
Ibogaine, a psychedelic drug, gains federal attention for treating addiction.
8/19/2026
Trump announces transfer of ibogaine investigational drug application to accelerate research.
8/16/2026
Research highlights ibogaine's potential in opioid addiction and multiple sclerosis.
8/15/2026
David Dardashti advocates ibogaine as a medical solution for kratom dependency.
8/13/2026
Former President Trump highlights ibogaine in discussions on addiction.
8/12/2026
NBC 7 San Diego video delves into ibogaine's impact on the brain.
8/12/2026
NBC San Diego reports on UC Irvine's ibogaine research and patient recovery.
8/10/2026
ARPA-H seeks to accelerate ibogaine trials for opioid treatment
8/8/2026
AtaiBeckley and Compass Pathways explore new opportunities.
8/7/2026
Rick Perry and Bryan Hubbard lead efforts to legitimize ibogaine in Texas.
8/6/2026
Police probe follows death linked to unauthorized ibogaine use in Canada.
8/5/2026
Thirty years of ibogaine studies reveal potential but highlight risks.
8/5/2026
Police charge Mississauga man after ibogaine-related death, highlighting risks.
7/31/2026
Mississippi explores ibogaine trials for addiction treatment, reflecting a shift towards health-centered drug policies.
7/30/2026
The institute seeks approval to study ibogaine's potential in treating addiction.
7/29/2026
Psychedelic trials often exclude marginalized groups, raising questions about equity and efficacy.
7/29/2026
State-led ibogaine study in Texas receives federal funding, advancing research into opioid treatment.
7/29/2026
Ibogaine HCl aims to treat PTSD, TBI, and opioid use disorder.
7/29/2026
State-led ibogaine study in Texas gains federal backing, marking a significant research development.
7/28/2026
YouTube video explores ibogaine's potential in treating disorders.
7/24/2026
White House adviser Heidi Overton shapes ibogaine policy amid internal disputes.
7/24/2026
Ibogaine research gains momentum under Trump administration's expedited process.
7/24/2026
The Tijuana-based center marks a milestone in ibogaine treatment for substance use disorder.
7/24/2026
The Trump administration considers making ibogaine available for therapeutic use.
7/23/2026
Ibogaine, a psychedelic, eyed for opioid crisis intervention under Trump.
7/23/2026
The amendment aims to expand treatment options for PTSD and addiction.
7/23/2026
YouTube video explores ibogaine's potential in treating addiction.
7/22/2026
Proposed NDAA amendment aims to expand treatment options for PTSD and TBI.
7/16/2026
Veterans report transformative effects from psychedelic therapy.
7/16/2026
Veterans share recovery stories, highlighting ibogaine's potential.
7/15/2026
New agreement includes ibogaine research for opioid use disorder.